February 24, 2018 |
Heart Failure System Significantly Reduced 30-Day Hospital Readmission Rates
November 19, 2014  | 

St. Paul, MN - St. Jude Medical, Inc., yesterday announced a retrospective data analysis from the CHAMPION clinical trial showing a significant reduction in 30-day hospital readmission rates for patients age 65 and older. The CHAMPION trial looked at the safety and effectiveness of the CardioMEMS HF System for patients with New York Heart Association (NYHA) Class III heart failure (HF) who had been hospitalized for HF in the previous 12 months. The analysis — Impact of Wireless Pulmonary Artery Pressure Monitoring on Heart Failure Hospitalization and All-Cause 30-Day Readmissions in Medicare-Eligible patients with NYHA Class III Heart Failure — was presented during the American Heart Association Scientific Sessions.

This analysis looked at patients 65 and older (Medicare-eligible) from the CHAMPION trial and found that there was a 58 percent reduction in all-cause hospital readmissions (hospitalization for any reason) and a 78 percent reduction in HF hospital readmissions when patients were managed with the CardioMEMS HF System compared to standard-of-care medical management. These findings suggest that use of the CardioMEMS HF System can significantly reduce the hospital’s risk of government-imposed penalties that are designed to reduce patient readmissions within 30 days of treatment. Continue>

Page | 1 2 3
Suggested Articles